Standout Papers
- Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells (1998)
- Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) (2007)
Citation Impact
Citing Papers
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
2018 StandoutScienceNobel
Intravital Imaging Reveals Transient Changes in Pigment Production and Brn2 Expression during Metastatic Melanoma Dissemination
2009
V600E BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway
2009
Differential Antigen Processing by Dendritic Cell Subsets in Vivo
2007 StandoutScienceNobel
Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells
2003
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
2014
Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen
2016
A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
2014
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
2014
High Frequency of Skin-homing Melanocyte-specific Cytotoxic T Lymphocytes in Autoimmune Vitiligo
1998
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
2006 StandoutNobel
Cutaneous ultraviolet exposure and its relationship to the development of skin cancer
2008
Hierarchical design of pseudosymmetric protein nanocages
2024 StandoutNatureNobel
Current and emerging systemic therapies for cutaneous metastatic melanoma
2019
Hallmarks of Cancer: The Next Generation
2011 Standout
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma
1999
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Dendritic cells as therapeutic vaccines against cancer
2005
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
2014 Standout
A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection
2001
Inflammation and cancer
2002 StandoutNature
Dendritic Cells as Vectors for Therapy
2001
Retinoic acid receptors: From molecular mechanisms to cancer therapy
2014
Analysis of the genome to personalize therapy for melanoma
2010
Physical Principles of Membrane Shape Regulation by the Glycocalyx
2019 StandoutNobel
The shared tumor-specific antigen encoded by mouse geneP1A is a target not only for cytolytic T lymphocytes but also for tumor rejection
1998
Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty
2012 Standout
Phase 1 Study in Patients With Metastatic Melanoma of Immunization With Dendritic Cells Presenting Epitopes Derived From the Melanoma-Associated Antigens MART-1 and gp100
2000
Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown
2018 StandoutNobel
Induction of cellular and humoral immune responses to tumor cells and peptides in HLA‐A24 positive hormone‐refractory prostate cancer patients by peptide vaccination
2003
A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients
2004
Mucin-1 is expressed on dendritic cells, both in vitro and in vivo
2004
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
2014 StandoutNature
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response
2009
Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells
2005
The use of dendritic cells in cancer immunotherapy
2003 StandoutNobel
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
2013 Nature
Psoriasis
2021 Standout
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
2003 Standout
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
Cancer immunoediting from immune surveillance to immune escape
2007
Antitumour actions of interferons: implications for cancer therapy
2016
Dendritic cells and tumor immunity
2001
Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
1999 StandoutNobel
HLA-A2 Restricted, Melanocyte-Specific CD8+ T Lymphocytes Detected in Vitiligo Patients are Related to Disease Activity and are Predominantly Directed Against MelanA/MART1
2001
Microbial Stimulation Fully Differentiates Monocytes to DC-SIGN/CD209+ Dendritic Cells for Immune T Cell Areas
2010 StandoutNobel
Natural selection of tumor variants in the generation of “tumor escape” phenotypes
2002
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
2010 Nature
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Cancer immunotherapy: moving beyond current vaccines
2004 Standout
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
2009
Bioengineered protein-based nanocage for drug delivery
2016
Crohn's disease
2016 Standout
Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: A pilot study
2000
Self-assembling protein nanoparticles in the design of vaccines
2015
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses
2002
Taking dendritic cells into medicine
2007 StandoutNatureNobel
Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells
2001
Common pitfalls in preclinical cancer target validation
2017 StandoutNobel
Identification of direct transcriptional targets of V600EBRAF/MEK signalling in melanoma
2009
Ulcerative colitis
2016 Standout
Dendritic Cells
1999
Atherosclerosis — An Inflammatory Disease
1999 Standout
Mature dendritic cells boost functionally superior CD8+ T-cell in humans without foreign helper epitopes
2000 StandoutNobel
Spinning molecular immunology into successful immunotherapy
2002
Generation and functional characterization of mouse monocyte-derived dendritic cells
1999
Molecular Dissection of Psoriasis: Integrating Genetics and Biology
2009
The First 1000 Dendritic Cell Vaccinees
2003
Progression of Mycosis Fungoides Is Associated with Increasing Cutaneous Expression of Interleukin-10 mRNA
1996
Cancer vaccines
1998
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
2012 StandoutNatureNobel
The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism
2009 Standout
Induction of carcinoembryonic antigen (cea)-specific cytotoxic t-lymphocyte responsesIn vitro using autologous dendritic cells loaded with cea peptide or cea rna in patients with metastatic malignancies expressing cea
1999
Dendritic cells and the control of immunity
1998 StandoutNatureNobel
Dendritic cell immunotherapy: mapping the way
2004
A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use
2000
Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine
2003
Peptide Vaccination for Patients With Melanoma and Other Types of Cancer Based on Pre-existing Peptide-Specific Cytotoxic T-Lymphocyte Precursors in the Periphery
2003
Clinical relevance of tumour-associated macrophages
2022
Dendritic cells transduced with TAT protein transduction domain‐containing tyrosinase‐related protein 2 vaccinate against murine melanoma
2003
Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma
2004
The control of T cell responses by dendritic cell subsets
2000
Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors
2002
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
2003
Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance
1999
Cross-Priming of Naive Cd8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Melanoma Cells
2000
Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.
2000
Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells.
2002
Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection
2001
Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2.
2001
Dendritic Cell Vaccines for Cancer Immunotherapy
1999
Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.
2001
Detection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals
2014 StandoutScienceNobel
Messenger RNA-Electroporated Dendritic Cells Presenting MAGE-A3 Simultaneously in HLA Class I and Class II Molecules
2004
Dendritic Cells Capture Killed Tumor Cells and Present Their Antigens to Elicit Tumor-Specific Immune Responses
2000
Systematic identification of signaling pathways with potential to confer anticancer drug resistance
2014
Structure of the STRA6 receptor for retinol uptake
2016 StandoutScienceNobel
Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization.
2001
Impaired Allostimulatory Capacity of Peripheral Blood Dendritic Cells Recovered from Hepatitis C Virus-Infected Individuals
1999
CELLULAR AND HUMORAL IMMUNE RESPONSES IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA AFTER VACCINATION WITH ANTIGEN PULSED DENDRITIC CELLS
1999
Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state.
2003
Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells.
2000
Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma
1999 StandoutNobel
Dendritic Cell-Based Vaccination in Solid Cancer
2002
Foxp3+ T reg cells control psoriasiform inflammation by restraining an IFN-I–driven CD8+ T cell response
2018
Identification of an IL-10-Producing HLA-DR-Negative Monocyte Subset in the Malignant Ascites of Patients with Ovarian Carcinoma That Inhibits Cytokine Protein Expression and Proliferation of Autologous T Cells
1999
Dendritic Cells in Cancer Immunotherapy
2000
Plasmacytoid predendritic cells initiate psoriasis through interferon-α production
2005
Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
2001 StandoutNobel
Cancer Immunotherapy: A Treatment for the Masses
2004 Science
Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients
2002
Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
2002
Immunization With Melan-A Peptide-Pulsed Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin-12 Induces Clinical Activity and T-Cell Responses in Advanced Melanoma
2003
Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells.
2000
Soluble Vascular Cell Adhesion Molecule-1 as a Biohumoral Correlate of Atherosclerosis
1997
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
2003 StandoutNobel
The Formation of Immunogenic Major Histocompatibility Complex Class II–Peptide Ligands in Lysosomal Compartments of Dendritic Cells Is Regulated by Inflammatory Stimuli
2000 StandoutNobel
Mage-3 and Influenza-Matrix Peptide-Specific Cytotoxic T Cells Are Inducible in Terminal Stage HLA-A2.1+ Melanoma Patients by Mature Monocyte-Derived Dendritic Cells
2000
Induction of Antitumor Immunity with Dendritic Cells Transduced with Adenovirus Vector-Encoding Endogenous Tumor-Associated Antigens
1999
Interleukin-10 and the Interleukin-10 Receptor
2001 Standout
Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
2002
Constitutive IL-10 Production Accounts for the High NK Sensitivity, Low MHC Class I Expression, and Poor Transporter Associated with Antigen Processing (TAP)-1/2 Function in the Prototype NK Target YAC-1
1998
Transport of Peptide-MHC Class II Complexes in Developing Dendritic Cells
2000 StandoutScienceNobel
Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells
2007
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors
1997 StandoutNobel
Understanding Melanoma Signaling Networks as the Basis for Molecular Targeted Therapy
2009
Dendritic Cells Charged with Apoptotic Tumor Cells Induce Long-Lived Protective CD4+ and CD8+ T Cell Immunity against B16 Melanoma
2003 StandoutNobel
Vaccination of Cancer Patients Against Telomerase Induces Functional Antitumor CD8+ T Lymphocytes
2004
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
2001 Standout
Proenkephalin+regulatory T cells expanded by ultraviolet B exposure maintain skin homeostasis with a healing function
2020 StandoutNobel
Immunobiology of Dendritic Cells
2000 Standout
Staining of interleukin-10 predicts clinical outcome in patients with nasopharyngeal carcinoma
1999
Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells
2003
Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning
2004
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
2010 StandoutNobel
Immunotherapy: Bewitched, Bothered, and Bewildered No More
2004 StandoutScienceNobel
Expansion of Melanoma-specific Cytolytic CD8+ T Cell Precursors in Patients with Metastatic Melanoma Vaccinated with CD34+ Progenitor-derived Dendritic Cells
2004
CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
1999
Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies
1999
Induction of CD4+ T cell–dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells
2002
Antigen-Specific Cytotoxicity by Invariant NKT Cells In Vivo Is CD95/CD178-Dependent and Is Correlated with Antigenic Potency
2010 StandoutNobel
Antigen Presentation and T Cell Stimulation by Dendritic Cells
2002
Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors
2002
TGF-β1 Reciprocally Controls Chemotaxis of Human Peripheral Blood Monocyte-Derived Dendritic Cells Via Chemokine Receptors
2000
Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines
1999
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
Lack of Phenotypic and Functional Impairment in Dendritic Cells from Chimpanzees Chronically Infected with Hepatitis C Virus
2004 StandoutNobel
Efficient Identification of Novel Hla-A*0201–Presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen Prame by Proteasome-Mediated Digestion Analysis
2001
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
2009 StandoutScience
Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
2012
Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases
2008
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
2002 StandoutNobel
Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein.
2001
Regulatory T cells in inflammatory skin disease: from mice to humans
2019
Works of Reinhard Dummer being referenced
In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States
2008
Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
2012
Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma
2008
Human CD271-Positive Melanoma Stem Cells Associated with Metastasis Establish Tumor Heterogeneity and Long-term Growth
2011
Disease-Independent Skin Recruitment and Activation of Plasmacytoid Predendritic Cells Following Imiquimod Treatment
2005
Aldara activates TLR7-independent immune defence
2013
Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective
2021
Intralesional Therapy With Anti-CD20 Monoclonal Antibody Rituximab in Primary Cutaneous B-Cell Lymphoma
2000
Circulating Intercellular Adhesion Molecule-1 in Melanoma Patients: Induction by Interleukin-2 Therapy
1992
New Perspectives in Experimental and Clinical Research for Cutaneous T Cell Lymphomas
1995
Transient MEK inhibitor-associated retinopathy in metastatic melanoma
2014
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature
2006
Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules
1997
Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma:in vitroand phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition
2012
EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer
2008
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
1998 Standout
Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
1997
Psoriasis Triggered by Toll-like Receptor 7 Agonist Imiquimod in the Presence of Dermal Plasmacytoid Dendritic Cell Precursors
2004
HLA-G and IL-10 expression in human cancer—different stories with the same message
2003
UV Protection and Skin Cancer
2002
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.
1998
Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab
2013
Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution
1998
Real-life Experience With Pegylated Interferon and Conventional Interferon in Adjuvant Melanoma Therapy
2012
Comparative analysis of immunocritical melanoma markers in the mouse melanoma cell lines B16, K1735 and S91-M3
2001
Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation
2018
Immune stimulatory potential of B7.1 and B7.2 retrovirally transduced melanoma cells: suppression by interleukin 10
1998
S-100B and FDG-PET/CT in Therapy Response Assessment of Melanoma Patients
2007
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
2013 Nature
Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00
2012
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
2008
Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma.
2012
Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma
2000
Nano‐particle vaccination combined with TLR ‐7 and ‐9 ligands triggers memory and effector CD 8+T ‐cell responses in melanoma patients
2012
Peripheral Blood Mononuclear Cells in Patients With Nonleukemic Cutaneous T-Cell Lymphoma
1993
AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study
2008
Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity
1991
Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma
2012
Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma.
2018
Vaccination of melanoma patients with peptide-pulsed dendritic cells
1997
Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.
2018
MEK1 mutations confer resistance to MEK and B-RAF inhibition
2009
European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies
2015
PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis
2016
Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma
2017
Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.
2016
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
2012
Serological detection of cutaneous T-cell lymphoma-associated antigens
2001
Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate–pulsed dendritic cells
2003
Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma.
2018